New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 7, 2012
17:49 EDTZGNXZogenix announces FDA panel votes against approval of Zohydro ER
Zogenix announced that the U.S. Food and Drug Administration's Anesthetic and Analgesic Drug Products Advisory Committee voted 2-11 against the approval of Zohydro ER, an extended-release formulation of hydrocodone without acetaminophen, for the management of moderate-to-severe chronic pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. "We remain confident in the measures we have proposed to support safe use of Zohydro ER and are committed to continuing to work with the FDA through the review process to bring this treatment option to this specific patient population," Zogenix COO Stephen Farr said. The Prescription Drug User Fee Act date for completion of FDA review of the Zohydro ER New Drug Application for approval is March 1, 2013.
News For ZGNX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2015
13:43 EDTZGNXZogenix epilepsy meeting abstracts encouraging, says Leerink
Leerink analyst Paul Matteis noted that three abstracts to be presented by Zogenix at the American Epilepsy Society were made available this morning, stating that new data on seven additional patients treated with fenfluramine add support to the clinical potential of the drug as a Dravet Syndrome treatment. Matteis reiterates an Outperform rating on Zogenix.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use